EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tracking prodromal α-synucleinopathies: novel fluid- and tissue-based biomarker approaches for iRBD phenoconversion

Giulia Bruschi, Elisa Bortolin, Salvatore Mazzeo iD, Alessandro Bombaci, Federico Emanuele Pozzi, Federica Agosta iD, Luigi Ferini-Strambi, Massimo Filippi iD, Maria Salsone

SLEEPJ · 2025

DOI: 10.1093/sleep/zsaf174 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift SLEEPJ, 2025. Verfasst von Giulia Bruschi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Synucleinopathies, REM Sleep Behavior Disorder, Prodromal Symptoms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 95 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isolated rapid eye movement sleep (REM) behavior disorder (iRBD) represents the strongest predictor of α-synucleinopathies, with over 90% of patients developing Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy after a decade. As such, iRBD provides a critical window for early diagnosis and intervention. While molecular imaging techniques have been widely explored as powerful biomarkers for early disease detection, validated, more accessible tests based on biospecimens capable of reliably predicting phenoconversion remain lacking, creating a crucial gap in the clinical management of at-risk individuals. This review provides a critical overview of the latest findings in biofluid and tissue-based biomarkers in iRBD, emphasizing the most promising candidates and outlining key directions for future research and clinical applications. While cerebrospinal fluid (CSF)-based α-synuclein has widely proven high diagnostic and prognostic accuracy, blood, urine, stool, skin, olfactory, and oral mucosa samples offer a feasible approach for scalable, population-level screenings in prodromal α-synucleinopathies. The development of multimodal biomarker panels combining accessible biofluids and tissue samples may pave the way for early intervention and more effective risk stratification in future neuroprotective trials for α-synucleinopathies. Statement of Significance This review provides an up-to-date synthesis of the most recent and high-impact studies on biomarkers in isolated rapid eye movement sleep (REM) sleep behavior disorder (iRBD). The growing emphasis on the applicability of less invasive and more clinically accessible biofluids and peripheral tissues reflects a broader clinical shift toward noninvasive approaches capable of supporting population-level screening and targeted interventions. Currently, no validated laboratory tests exist in clinical practice to reliably predict iRBD phenoconversion to overt α-synucleinopathies, creating a critical gap in early stage disease management. The insights presented here will be essential for developing early diagnostic tools and refining patient stratification strategies, both of which are essential for upcoming disease-modifying trials targeting early stage α-synucleinopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SynucleinopathiesREM Sleep Behavior DisorderProdromal SymptomsHumansBiomarkersalpha-SynucleinEarly DiagnosisParkinson Disease

Stichwörter der Autor:innen

biomarkerisolated REM sleep behavior disorder (iRBD)neurodegenerationα-synucleinopathies

Substanzen

Biomarkersalpha-Synuclein

Autor:innen und Institutionen

  • Department of Psychology, Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Neurology, Vita-Salute San Raffaele University, Milan, Italy.
  • Neurology unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy.
  • Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, IRCCS Ospedale San Raffaele Hospital, Milan, Italy.
  • Department of Clinical Neurosciences, Neurology-Sleep Disorders Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.

ORCID-Profile: Salvatore Mazzeo, Federica Agosta, Massimo Filippi

Zitieren

APA

Bruschi, G., Bortolin, E., Mazzeo, S., Bombaci, A., Pozzi, F. E., Agosta, F., Ferini-Strambi, L., Filippi, M., & Salsone, M. (2025). Tracking prodromal α-synucleinopathies: novel fluid- and tissue-based biomarker approaches for iRBD phenoconversion. SLEEPJ. https://doi.org/10.1093/sleep/zsaf174

Vancouver

Bruschi G, Bortolin E, Mazzeo S, Bombaci A, Pozzi FE, Agosta F, et al. Tracking prodromal α-synucleinopathies: novel fluid- and tissue-based biomarker approaches for iRBD phenoconversion. SLEEPJ. 2025. doi:10.1093/sleep/zsaf174

BibTeX
@article{Bruschi2025,
  author = {Bruschi, Giulia and Bortolin, Elisa and Mazzeo, Salvatore and Bombaci, Alessandro and Pozzi, Federico Emanuele and Agosta, Federica and Ferini-Strambi, Luigi and Filippi, Massimo and Salsone, Maria},
  title = {Tracking prodromal α-synucleinopathies: novel fluid- and tissue-based biomarker approaches for iRBD phenoconversion},
  journal = {SLEEPJ},
  year = {2025},
  doi = {10.1093/sleep/zsaf174}
}
Kostenlos starten →